- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nycomed and VHA sign five-year deal
Nycomed has secured a five-year agreement with VHA, the nation's largest health-care network,to provide its nonionic imaging agent Omnipaque (iohexol) underthe VHA Plus label. It is the second such contract signed recently by Nycomed andVHA. In October
Nycomed has secured a five-year agreement with VHA, the nation's largest health-care network,to provide its nonionic imaging agent Omnipaque (iohexol) underthe VHA Plus label.
It is the second such contract signed recently by Nycomed andVHA. In October 1994, the companies agreed to a three-year pactpermitting VHA Plus labeling of Omniscan (gadodiamide), a nonionicMRI imaging agent.
The private labeling deal permits VHA to market the agentsto its network of 1132 health-care organizations, which representnearly one of five U.S. hospitals. The network purchases $6 billionworth of supplies and services annually through VHA contracts,Nycomed officials said.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
